Title : Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer.

Pub. Date : 2019 Dec

PMID : 31621403






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer. Tyrosine epidermal growth factor receptor Homo sapiens
2 Aim: EGFR-tyrosine kinase inhibitors (TKIs) vary in efficacy, side effects (SEs) and dosing regimen. Tyrosine epidermal growth factor receptor Homo sapiens